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Abstract 87 
 88 
Epigenetic alterations, such as those linked to DNA methylation, may potentially 89 
provide molecular explanations for complications associated with altered gene 90 
expression in illnesses, such as chronic kidney disease (CKD). While both DNA hypo- 91 
and hypermethylation have been observed in the uremic milieu, this remains only a 92 
single aspect of the epigenetic landscape and, thus, of any biochemical dysregulation 93 
associated with CKD. Nevertheless, the role of uremia-promoting alterations on the 94 
epigenetic landscape regulating gene expression is still a novel and scarcely studied 95 
field. Though few studies have actually reported alterations of DNA methylation via 96 
methyl donor nutrients intake, emerging evidence indicates that nutritional modification 97 
of the microbiome can affect one carbon metabolism and the capacity to methylate the 98 
genome in CKD. In this review, we discuss about the nutritional modifications that may 99 
affect one carbon metabolism and, the possible impact of methyl donor nutrients on the 100 
microbiome, CKD and its phenotype. 101 
 102 
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1. Introduction 104 
Chronic kidney disease (CKD) with a global prevalence of 10-15% represents a 105 
public health problem worldwide (1). CKD patients present with many complications, 106 
including persistent low-grade inflammation and oxidative stress, which are important 107 
contributors to adverse outcomes, such as cardiovascular disease (CVD) (2). Inter-108 
individual variation in disease progression and response to therapy remains substantial 109 
and the underlying factors contributing to this variation remain largely unknown. One 110 
potential source of this variation resides in  epigenetic differences and in particular, the 111 
epigenetic landscape of ageing (3, 4), as CKD manifests as a disease of accelerated 112 
ageing (5). The epigenetic landscape of ageing refers to the interplay, over the life 113 
course, between the environment and canonical features of the genomic methylome and 114 
chromatin structure, along with non-canonical features, such as the co-ordinated 115 
regulation of a broad range of cellular biochemistry by non-coding RNAs (3,4,5). 116 
Epigenetic regulation of the process of ageing is influenced directly by various 117 
factors, including nutrition, inflammation, the gut microbiome, psychosocial and 118 
lifestyle factors (3). Understanding how the epigenetic landscape changes in CKD 119 
would offer novel approaches to better understanding the uremic phenotype. For 120 
example, tailor-made interventions to target the underlying biochemistry of canonical 121 
epigenetic features via the nutritional acquisition of methyl donors required for 122 
maintenance of the methylome. 123 
 124 
1.1 What is epigenetics and how is it regulated? 125 
Epigenetics refers to heritable changes that are not coded for in the underlying 126 
DNA sequence. They enable a means of changing phenotype without changing the 127 
genotype. Epigenetic regulation of gene expression allows for rapid physiological 128 
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adaptations to environmental change, critical for development and homeostasis. In their 129 
canonical form, epigenetic modifications involve DNA methylation or histone 130 
modification (via methylation, acetylation, phosphorylation, ubiquitylation, and 131 
sumolyation) (3, 6). Such epigenetic changes regulate and coordinate access for 132 
transcriptional machinery to adjust gene expression, thus enabling changes in phenotype 133 
without changes in genotype. Additionally, at a non-canonical level, reciprocal 134 
regulatory networks of non-coding RNAs integrate canonical features within the greater 135 
epigenetic landscape (4, 6).  136 
The activation and repression of gene transcription by DNA methylation can be 137 
influenced by a range of factors including uremia and metabolic features, such as 138 
hyperhomocysteinemia, oxidative stress and inflammation (3-7). There is a paucity of 139 
information available on the methylome in CKD, which demands that knowledge of 140 
exactly how, when, where and which genes are activated or repressed as a consequence 141 
of methylation-induced changes. Additionally, how the ensuing physiological changes 142 
occur, must be viewed in the context of the overall epigenetic landscape of ageing. 143 
Unsurprisingly, both global hypo- (8) and hyper-methylation (9) have been reported in 144 
CKD. While accelerated ageing inherent in CKD should typically result in genomic 145 
hypomethylation and acceleration of a methylation based epigenetic clock, individual 146 
genes may show hypermethylation of their promoters or other regulatory elements, 147 
reflective of the human genome encodes diminution/loss of expression and thus 148 
decreased functional activity (2, 3). However, the biological context of any equivocal 149 
reports indicating an increase in global methylation remains unknown and requires 150 
evaluation (10). Epigenetic studies in CKD are, thus, important for better understanding 151 
the variable and complex uremic phenotype (11). 152 
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Studies on epigenetic modifiers that can modulate features of the epigenetic landscape 153 
are scarce. Maintenance of the methylome is critical to the integrity of the epigenome. 154 
This is regulated via one carbon metabolism and, thus, in turn by nutritional input of 155 
methyl donors, such as Met, folate, vitamin B-12, choline and betaine which are 156 
substrate providers for many epigenetic processes (12, 13). Little is known about how 157 
nutrients affect epigenetic processes in CKD. Hence this review seeks to evaluate the 158 
evidence of epigenetic changes in CKD involving DNA methylation and, discuss the 159 
possible impact of methyl donor nutrients and their influence on the microbiome, as 160 
putative modifiers of CKD and its phenotype. 161 
 162 
 163 
 164 
1.2 The principles and the evidence for methylation dynamics in CKD 165 
DNA methylation, a dynamic and flexible means of modulating the response of 166 
the genome to environmental stimuli, is an inherent component of natural biological 167 
processes, such as ageing, that may reflect or possibly explain dysregulation in disease 168 
processes (13, 14). Typically, this comprises the transfer of a methyl group (CH3) from 169 
the universal methyl donor, S-adenosyl-L-methionine (SAM), to the 5-position of 170 
cytosine residues in DNA by DNA methyltransferases (DNMTs) enzymes, to form 5-171 
methylcytosine (15, 16). 172 
DNA methylation in mammals is highly regulated and DNMT activity can be 173 
modulated by numerous interactions with a diverse set of cofactors, post-translational 174 
modifications, alternative splicing and gene loss and duplication (15, 16, 17). DNA 175 
methylation patterns are considered the key markers of epigenetic programming and 176 
play an important role in maintaining genome integrity, disruption of which may result 177 
in chromosome instability. In human disease, altered DNA methylation patterns are one 178 
of the earliest and most consistent molecular changes observed (3, 18). 179 
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DNA methylation generally occurs within the context of CpG dinucleotides, 180 
where methylation permits methylation-binding proteins to bind to the site, repressing 181 
transcription via recruitment of chromatin remodeling factors. Most CpG sites within 182 
the mammalian genome are methylated, including CpGs found in and between genes 183 
(intronic and intergenic regions respectively) (18, 19). In contrast, regions which are 184 
enriched for CpG sites, termed “CpG islands,” are commonly depleted of methylated 185 
DNA, allowing an open chromatin structure and binding of transcription factors. CpG 186 
islands are highly conserved between mice and humans and approximately 70% of all 187 
gene promoters are found in CpG islands (4) (Figure 1). 188 
Regulation of DNMT activity can be influenced directly by nutrition via one 189 
carbon metabolism. Nutritionally acquired Met, for example, is a direct precursor for 190 
SAM, a universal methyl donor for several transmethylation pathways involving dietary 191 
nutrient-dependent enzymes (Figure 2). These include serine hydroxymethyl transferase 192 
(SMHT), with vitamin B-6 as a cofactor, methylenetetra-hydrofolate reductase 193 
(MTHFR) with vitamin riboflavin as a cofactor, Met synthase with vitamin B-12 as a 194 
cofactor, choline dehydrogenase (CHDH) with vitamin choline as cofactor and betaine 195 
homocysteine methyltransferase (BHMT) with betaine as a cofactor, After a methyl 196 
group is removed from SAM by one of the respective DNMTs, S-adenosyl-197 
homocysteine (SAH) is formed by the action of SAH hydrolase; this is hydrolyzed to 198 
homocysteine, which then enters into Met cycle (discussed below) (14, 18). In this way, 199 
SAH competes with the activity of DNMTs and acts as a powerful competitive inhibitor 200 
of SAM. Consequently, it plays an important role in maintenance of the cellular 201 
methylome (7, 19). 202 
In CKD, dynamic methylation at CpG islands is an inherent feature of epigenetic 203 
regulation, observed in vitro, in pre-clinical animal models and human studies (4, 20, 204 
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21, 22, 23). Notable examples of such regulation pertinent to renal biology, include 205 
hypermethylation of the RAS protein activator like 1 (Rasal1) gene (encoding an 206 
inhibitor of the Ras oncoprotein) causing kidney fibrosis in mice and suppression of 207 
Klotho activity (considered a regulator of ageing) through hypermethylation induced by 208 
microbial derived uremic toxins, such as indoxyl sulfate and p-cresyl sulfate (20). 209 
Notably, renal fibrosis has also been linked to the presence of senescent renal cells in 210 
CKD and links changes in the epigenetic landscape of ageing to pathological features of 211 
the disease (21). 212 
Epigenetic change in CKD is further exemplified by the MTHFR gene. Its 213 
enzymatic product is MTHFR, which promotes methyl radical synthesis in the 214 
homocysteine cycle, and can provide methyl groups for DNA methylation. MTHFR 215 
catalyzes the reduction of 5,10-methyl-tetrahydrofolate (THF) to 5-methyl-THF, in 216 
order to form Met from homocysteine, the concentration of which increases in CKD and 217 
is associated with increased CVD risk (22). CKD patients also display a significant up-218 
regulation in the methylation at the MTHFR promoter, commensurate with decreased 219 
production of this enzyme (22). In turn, this is expected to contribute to a loss of global 220 
genomic methylation correlating with increasing biological age (13, 16). 221 
In practice, however, extrapolating methylation changes at a given locus to a 222 
global picture of the epigenome in the uremic environment is challenging and complex. 223 
Differences in methodology and in techniques for assessment of DNA methylation 224 
changes have contributed to equivocal reports when applied to such analyses in CKD 225 
cohorts (7). Both Zinellu et al. (8) and Nanayakkara et al. (23) have demonstrated DNA 226 
hypomethylation in whole blood from CKD patients, while Hsu et al. (24), observed no 227 
such methylation loss, but did observe reduced DNMT3b transcription, supporting loss 228 
of regulation of the methylome with age and disease. In contrast, Stenvinkel et al. (9) 229 
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reported that inflamed CKD patients exhibited global DNA hypermethylation, which 230 
was associated with CVD and increased mortality. Recently, Ghigolea et al. (25), 231 
evaluating 80 haemodialysis (HD) patients, also reported global DNA hypermethylation 232 
in whole blood in dialysis patients compared to healthy individuals.   233 
Evaluation of renal function associated with methylome changes in the general 234 
population has also identified a strong association with genes involved in ageing 235 
processes. Bomotti et al. (26) investigated the methylation status of 14,000 genes and 236 
their relationship with eGFR in the GENOA Study. The top ranked candidates showing 237 
significant methylation changes correlating with variation in kidney function were 238 
involved in regulating the ageing process and inflammation. Notably, a high rank was 239 
observed for Krüppel-like transcription factor 2, which has a role in regulating blood 240 
flow through the glomerular kidney bed and regulation of most of the nuclear factor 241 
kappa B (NF-ΚB)-mediated activities, including inflammatory and fibrotic processes 242 
(27). This provides a rational basis for linking changes in epigenetic status with renal 243 
function in CKD. However, a more recent epigenome wide association study of kidney 244 
function and CKD in 4859 participants from the general population only identified 245 
DNA methylation changes at 19 CpGs that were associated with estimated glomerular 246 
filtration rate (eGFR) or CKD at epigenome-wide significance (28). This indicates the 247 
complexity in evaluating the directional nature of any methylation dynamics in CKD, 248 
relating to cause, effect and ageing. 249 
 250 
1.3 How might nutrition impact on the epigenome in CKD? 251 
As changes to the methylome are, context dependent, typically in response to 252 
dynamic environmental cues, it is worth discussing the impact of nutrition and how this 253 
may lead to observed differences in distinct clinical cohorts (3, 4, 5). A range of 254 
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nutritional factors feeding into one carbon metabolism will be discussed and evaluated 255 
for their capacity to influence changes in the epigenetic landscape. 256 
 257 
2. Methyl Donor Nutrients 258 
Methyl donor nutrients, such as Met, folate, vitamin B-12, choline and betaine 259 
are substrate providers for many epigenetic processes (29). For example, both maternal 260 
folate and choline supplementation during pregnancy can cause epigenetic alterations to 261 
genes in offspring (30). While most studies show positive health-effects associated with 262 
methyl donor supplementation, mounting evidence has also indicated the potential for 263 
deleterious effects, including an increased risk of cancer and neurological disorders (31, 264 
32). The impact of dietary methyl donors in CKD remains to be fully elucidated. It is, 265 
thus, pertinent to discuss the relative and respective merits of nutritionally derived 266 
methyl donors in the context of uremia. 267 
 268 
2.1 Methionine 269 
Met, an essential Sulphur-containing amino acid, is a central molecule in one-270 
carbon metabolism. Maintaining an adequate level of Met derived via nutritional intake, 271 
19 mg/kg/day of methionine + cysteine according to Institute of Medicine (IOM, 2005), 272 
is essential for ensuring an appropriate level to enable sufficient DNA methylation, 273 
facilitated by SAM production. Variation of the amount of Met in the diet can influence 274 
DNA methylation levels and consequently contribute to the dysregulation of gene 275 
expression (33).  276 
Red meat is predominantly abundant in Met content per total protein content, 277 
and high frequency of red meat consumption is associated with accelerated ageing and 278 
diminished renal function in man (34) and in animals (35). Met restriction can be 279 
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achieved through a vegan diet, however as Met is an essential amino acid it cannot be 280 
entirely removed from diet (36). Restriction of Met may extend longevity (37), improve 281 
glucose and lipid metabolism and reduce oxidative stress (38). This postulate is 282 
supported by a range of in vitro and in vivo pre-clinical models, indicating altered 283 
methylation profiles in a variety of human diseases (39, 40), that can be directly affected 284 
by altered Met levels in the diet (40).  285 
Met restriction is particularly pertinent to renal biology. Indeed, Cooke et al. (41) 286 
recently showed that kidneys in 5/6 nephrectomized mice play an important role in 287 
maintaining osmotic balance during Met restriction diet, by up-regulating genes 288 
involved with ion transport. Additionally, Met restriction may delay the progression of 289 
CKD by down-regulating inflammatory and fibrotic processes. This results in lower 290 
expression of  urinary biomarkers normally elevated during kidney disease (41). 291 
Correspondingly therefore, a high Met diet may induce elevated levels of oxidative 292 
stress and elevate renal damage in kidneys with tubular hypertrophy (42,43). 293 
Surprisingly therefore, , Amaral et al. (44) have reported that a high Met diet is not 294 
deleterious to kidney cells in Wistar rats. Furthermore, dietary Met supplementation did 295 
not alter the SAM/SAH ratio, nor DNA methylation at the promoter region of the tumor 296 
suppressor gene p53. However, it did result in restoration of glutathione levels in 297 
animals  treated with doxorubicin. 298 
 299 
2.2 Folate 300 
Folate is the term used to describe a range of forms of the water-soluble vitamin 301 
B-9 that occurs naturally in foods (Table 1) (41,45). Dietary folate has an important role 302 
in the formation of SAM, and can be a limiting factor in the associated pathway. In the 303 
folate cycle (Figure 1), folate is imported into cells and metabolized into its active form 304 
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THF, which is converted to 5,10-methyl-THF by hydroxymethyl transferase (vitamin B-305 
6 as cofactor). It is then reduced to 5-methyl-THF by MTHFR (riboflavin as cofactor), 306 
and to complete the folate cycle, 5-methyl-THF is demethylated to form THF. With the 307 
demethylation of 5-methyl-THF, the methyl group is donated into the Met cycle through 308 
the methylation of homocysteine by Met synthase and its cofactor vitamin B-12 (42, 43, 309 
46, 47). 310 
The ability of folate to lower homocysteine levels indirectly suggests it might 311 
have a positive influence on CVD, considering that high homocysteine plasma levels 312 
are linked to cardiovascular mortality in CKD (7). Accordingly, HD patients display 313 
low folic acid intake, low folate serum levels and high homocysteine levels (44, 48). 314 
Thus, folic acid therapy may be an important factor for these patients. Indeed, in a study 315 
targeting the high homocysteine levels in CKD, folate supplementation reduced but did 316 
not normalize plasma homocysteine levels (45, 49). However, other studies have 317 
reported no consistent effect of extended supplementation with folic acid on 318 
homocysteine levels in CVD and CKD cohorts (46, 47, 50, 51). An insight into these 319 
equivocal reports can be gained from Xiao et al. (19) who have discussed how elevated 320 
plasma homocysteine levels are associated with an increased risk of CVD, and why 321 
some intervention studies with vitamin B and folic acid supplementation are not able to 322 
reduce its levels. One possibility is that homocysteine is simply a marker of increased 323 
CVD risk and that SAH accumulation may be the cause of increased risk. Studies on 324 
atherosclerosis, CKD, diabetes and obesity have all shown that SAH levels better reflect 325 
an increased cardiovascular risk than homocysteine (48, 49, 52, 53). One proposed 326 
mechanism is that SAH promotes apoptosis of endothelial cells, independently 327 
of homocysteine levels, and enhances Dihydronicotinamide-adenine dinucleotide 328 
phosphate (NADPH) oxidase expression, increasing the production of reactive oxygen 329 
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species (50, 54). Furthermore, SAH is a powerful competitive inhibitor of SAM, which 330 
is also increased, both intra- and extracellularly, in various pre-clinical models of 331 
hyperhomocysteinaemia, including uremia (51,55). As a result, several methyl transfer 332 
reactions may be impaired, suggesting that methylation biochemistry is imbalanced (52, 333 
56). High levels of homocysteine and SAH can then be associated with altered DNA 334 
methylation profiles in CKD (7). It is worth mentioning, however, that while 335 
homocysteine levels are linked to DNA methylation profiles (53, 57), these may be 336 
specific to subsets of genetic elements and not to the DNA global methylation levels. 337 
Global DNA hypomethylation is more typically observed in most non-communicable 338 
and age related diseases. It is notable that confounding factors, such as inflammation, 339 
oxidative stress, dyslipidemia and folate supplementation, may explain the lack of 340 
agreement in reports from disparate clinical studies (52, 53, 56, 57). 341 
 342 
2.3 Vitamin B-12 343 
Vitamin B-12, a water-soluble vitamin, is one of eight B vitamins naturally present in 344 
animal and dairy products, and generally not present in plant foods. (Table 1) (54, 58). 345 
Vitamin B-12, together with folate, plays a key role in the formation of SAM in one-346 
carbon metabolism (Figure 1) and works as a coenzyme for Met synthesis via its action 347 
in the transfer of the methyl group from 5-methyl-THF to homocysteine to form Met 348 
(55, 59). Vitamin B-12 deficiency is associated with anemia and neurological disorders., 349 
Additionally, low vitamin B-12 is associated with higher plasma homocysteine, a risk 350 
factor for CVD (60). Impairment of its conversion to Met leads to DNA 351 
hypomethylation (56, 61). a key feature of normal ageing processes. 352 
Correspondingly, CKD patients also have high prevalence of vitamin B-12 353 
deficiency, in keeping with it being a disease of accelerated ageing (62). Furthemore, in 354 
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an observational cohort study, it has been shown that vitamin B-12 is not associated 355 
with albuminuria or reduced kidney function in both a univariate or multivariable-356 
adjusted models. However, in patients with elevated homocysteine levels, higher 357 
vitamin B-12 concentrations were associated with an increased prevalence of reduced 358 
kidney function. The combination of elevated homocysteine along with increased B-12 359 
suggests the possibility of a resistance to the usual effects of vitamin B-12 in these 360 
individuals (63). Moreover, Soohoo et al. (64) observed association between high 361 
vitamin B-12 levels and mortality in HD patients. In patients with higher predisposition 362 
to inflammation, such as the HD population, decreased production of transcobalamin II 363 
may lead to reduced uptake of circulating vitamin B-12 by peripheral tissues, and 364 
heightened synthesis of transcobalamins I and III further augment accumulation of B-12 365 
in serum (64).  366 
The ratio of folic acid and vitamin B-12 may play an important role in determining 367 
global DNA methylation levels. Indeed, it has been reported, that a vitamin B-12 368 
deficient diet, although with maternal folic acid supplementation, reduced total global 369 
DNA methylation levels in rats (57, 65). In human studies, children of mothers who had 370 
lower vitamin B-12 intake and high folate concentrations, presented insulin resistance 371 
and adiposity, suggesting that defects in one-carbon metabolism might be fundamental 372 
to intrauterine programming of adult disease (58, 66).  373 
 374 
2.4 Choline  375 
 Choline, a natural amine recognized as an essential nutrient, is widely distributed 376 
in foods, mostly in the form of phosphatidylcholine in the cell membranes (54, 58). 377 
Although choline can be synthesized in the liver, via the sequential methylation of 378 
phosphatidylethanolamine, the amount that the body naturally synthesizes is not 379 
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sufficient to meet human requirements (59, 67). Current evidence suggests that nearly 380 
90% of adults do not achieve the recommended daily adequate intake of choline (425 381 
and 550 mg/day for women and men, respectively) (61, 68). Choline deficiency leads to 382 
increased plasma homocysteine levels (thus there is a diminished capacity to methylate 383 
homocysteine to form Met), which is associated with CVD and cognitive decline 384 
(62,69) among other diseases, as well as genomic DNA hypomethylation through 385 
reduced tissue levels of SAM (63, 70).  386 
Under physiological conditions choline is excreted through urine. However, in 387 
CKD patients this methyl donor is accumulated. In dialysis patients, choline is cleared 388 
and plasma free choline concentration falls during hemodialysis, but returns to baseline 389 
levels 6 hrs later (71). Epidemiological studies have found that a high blood choline 390 
level is positively associated with metabolic syndrome (or dyslipidemia) (72) and 391 
major adverse cardiovascular events (73, 74). It is unclear whether choline itself, or 392 
metabolites like trimethylamine-N-oxide (TMAO), the production of which initially 393 
requires the metabolic activities of gut microbiota to generate it, contributes to the 394 
adverse events experienced by individuals with high choline intake (75). Indeed, 395 
several human studies have associated high levels of TMAO to CVD (76, 77, 78 ,79, 396 
80). Moreover, a direct inverse relationship between TMAO levels and renal function 397 
has been observed, with a severe elevation of TMAO seen in advanced CKD (77,81). 398 
Coinciding with this, TMAO has widely been identified as a promoter of atherosclerosis 399 
(70, 82), and accelerated atherosclerosis is exacerbated in patients suffering from CKD 400 
compared to those with normal renal function.  401 
 402 
2.5 Betaine 403 
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Betaine (glycine betaine, N,N,N-trimethylglycine) is an important non-essential 404 
nutrient derived from either dietary intake, or via choline oxidation. The latter involves 405 
choline oxidation to betaine aldehyde in the inner mitochondrial membrane, and then to 406 
betaine; both oxidation steps are catalyzed by CHDH. This reaction is essentially 407 
irreversible, as betaine cannot be reduced back to choline (71, 83). Betaine is found in a 408 
variety of food sources (Table 1) and its main physiological role is as a methyl donor, 409 
playing an essential role in the transition from homocysteine to Met, catalyzed by 410 
BHMT. Thus, betaine regulates the concentrations of SAH and is essential for one-411 
carbon metabolism (72, 73, 74, 84).  412 
Just like choline, betaine is a TMA-containing nutrient, that leads to the 413 
production of TMAO (74, 81). This uremic toxin is elevated in CKD, and is associated 414 
with high risks of progressive renal fibrosis, thereby significantly increasing mortality 415 
rates from the disease (75, 85).  416 
 417 
3. The microbiome - linking “inflammaging” to the epigenome 418 
A growing body of evidence has indicated that social, psychological life style 419 
and nutritional risk factors influence the trajectory of age related health and age related 420 
morbidities by acting either independently, cumulatively, or synergistically with an 421 
individual’s genetics, and in particular epigenetics, thus determining health span (3). 422 
Accelerated biological ageing (i.e. ‘miles on the clock’) is also a feature of age related 423 
morbidities, where disease specific processes are layered upon dysregulated ageing 424 
processes. This thesis has been extensively exemplified for the kidney, where CKD has 425 
been classified as a condition of accelerated ageing (5) + Stenvinkel P, Larsson T. Chronic 426 
kidney disease – a model of premature aging. Am J Kidney Dis. 2013 Aug;62(2):339-51. 427 
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Mechanistic insight into how dietary and epigenetic factors regulate ageing 428 
throughout the life-course, linked to a decline in renal function with ageing, is already 429 
proving of significant value (34). Recently, evidence has emerged indicating that (i) 430 
epigenetic regulation of nutrient sensing pathways and (ii) nutritional differences tied to 431 
socioeconomic position, can differentially affect the renal ageing process in particular 432 
age-related genomic hypomethylation and inflammatory status. In both instances, renal 433 
function reflected changes in ageing processes and their associated epigenetic regulation 434 
(3, 34). 435 
An outstanding problem, however, remains identifying factors driving 436 
“inflammaging”. Intuitively, the burden of aged (senescent) cells generates a pro-437 
inflammatory environment via a senescence associated secretory phenotype (SASP), 438 
that poison the surrounding tissue. However, in epidemiological cohorts, <15% of the 439 
level of systemic inflammation can be explained on the basis of cellular aging.  440 
A key component of the inflammatory burden of ageing may be provided by the 441 
microbiome. The human microbiome refers to the entire collection of genetic material 442 
belonging to the microorganisms residing within the human body, including bacteria, 443 
archaea, fungi, viruses, helminths and protozoa (76, 86). The microbiome is an integral 444 
part of the normal host function, and a mutual relationship exists between the human 445 
body and its associated microbiome (77, 87). A particular element of the microbiomes 446 
function, which is crucial to its host is its ability to provide a means of metabolising 447 
otherwise inaccessible nutrients needed for example, for the production of short chain 448 
fatty acids during energy metabolism (78, 88). The microbiome also produce 449 
metabolites, which are necessary for amino acid production essential to the host, and in 450 
turn is associated with maintaining our epigenetic landscape (3, 4). 451 
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As the gut microbiome changes with both chronological and biological age (79, 452 
89), one novel hypothesis that has gained much attraction is that the microbial 453 
metabolite TMAO is central to the inter-relationship between “inflammaging”, health 454 
span and the age-related epigenome. This pro-atherogenic and pro-inflammatory 455 
compound is derived from microbial metabolism of phosphatidylcholine, L-carnitine 456 
and lecithin, which are found in red meat, fish and eggs, so providing a mechanistic link 457 
between nutrition, ageing and the epigenome (3, 35). Production of TMA, the TMAO 458 
precursor, was also observed to be greater in frail older people that consumed a 459 
restricted diet than healthy older people, in a manner that could be linked to differences 460 
in their microbiome coding capacity (80, 90). There is also a further emerging role for 461 
the microbiome in epigenetics through production of butyrate that inhibits histone 462 
deacetylases (81, 91).  463 
     In CKD, microbial dysbiosis correlates with altered metabolism of proteins and 464 
amino acids leading to the production of toxic compounds including ammonia, phenols, 465 
indoles and most notably TMAO (2, 35). A study into the intestinal microbial 466 
populations of Chinese CKD patients found eight genes associated with TMAO 467 
production. One of these genes was associated with betaine metabolism and showed 468 
reduced expression in CKD. This suggests that gut dysbiosis leads to abnormal betaine 469 
metabolism, thus producing a redundant level of TMA free to be oxidised to toxic 470 
TMAO (91). Thus, monitoring the dietary intake of TMA producing nutrients, such as 471 
betaine, choline and L-carnitine, along with the identification of key members of the gut 472 
microbiota associated with their metabolism offer potential therapeutic strategies to 473 
alleviate the burden of renal disease.  474 
  In addition, the loss of symbiosis in the gut also contributes to impaired 475 
intestinal epithelial barrier function leading to translocation of bacterial-derived uremic 476 
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toxins into the systemic circulation (92). This contribute to inflammation, protein-477 
energy wasting, insulin resistance, and exacerbation of the risk of CVD during CKD 478 
progression (93). With these links between nutrition, microbial metabolism and 479 
epigenetic regulation in mind, studying the interplay between these key factors are 480 
important to further investigations into CKD progression, and could offer a potential 481 
therapeutic target.  482 
 483 
4. Conclusions 484 
Nutrient intake has a direct effect on the epigenome and emerging evidence is 485 
highlighting a complex interplay with the microbiome. This is both pertinent to age- 486 
related health and inflammation and involves modulation of one-carbon metabolism. 487 
This aspect of cellular biochemistry is of interest in CKD, as the exposure to a 488 
physiologically aberrant uremic milieu is a potential factor in the promotion of 489 
dysregulation of the epigenetic landscape. Additionally, any nutritional impact on the 490 
microbiome and its interaction with host physiology will again directly affect the 491 
epigenome. Alteration of the microbiome is a known feature of both CKD and 492 
“inflammaging”. It is intuitive to consider the modulation of the microbiome, either by 493 
variation in diet, or by restoration of microbial diversity in the gut using live bio-494 
therapeutics (i.e. implantation of hub microbes to alter diversity), to mitigate loss of 495 
diversity with ageing or in accelerated ageing linked to morbidities, such as CKD. 496 
Studies evaluating the effects of dietary supplementation, such as methyl donor 497 
nutrients, on the epigenome of CKD and gut microbiota metabolism, remain limited. 498 
Future studies are merited as a link is intuitive and may easily achieve direct clinical 499 
benefit. One further benefit from such approaches may be a reduction of age or disease 500 
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related inflammatory burden. This is again easily investigated, achievable and merits 501 
action. 502 
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Figure 1. Methylation playing a crucial role in gene expression 754 
DNA methyltransferases (DNMTs) catalyze the transfer of a methyl group (CH3) to the 755 
5-position of a cytosine, generating 5-methylcytosine. This chemical modification 756 
inhibits gene expression when areas rich in CpG (CpG Island) are present within 757 
promoter regions. 758 
 759 
Figure 2. Dietary nutrients and one-carbon metabolism 760 
One-carbon metabolism comprises the folate cycle and the methionine cycle that are 761 
interconnected in a complex process involving dietary nutrients as substrates or 762 
enzymatic cofactors. These nutrients and their respective dietary sources are depicted 763 
above. Dietary folate is metabolized into THF, which is converted to 5,10-methyl THF 764 
and finally to 5-methyl THF, which is demethylated and donates the methyl group into 765 
the methionine cycle through the methylation of homocysteine by a methionine 766 
synthase B-12-dependent reaction. Homocysteine can also receive a methyl group from 767 
betaine to form methionine. Methionine is then converted to SAM, the universal methyl 768 
donor required for DNA methylation. After the methyl group is transferred from SAM 769 
to the DNA molecule, forming 5-Methylcitosyne, SAH is formed and hydrolyzed to 770 
homocysteine, which returns to methionine cycle. 771 
BHMT: betaine homocysteine methyltransferase; DNMT: DNA methyltransferase; 772 
MTHFR: methylenetetrahydrofolate reductase; SAH: S-adenosylhomocysteine; SAM: 773 
S-adenosylmethionine; SHMT: serine hydroxymethyl transferase; THF: form 774 
tetrahydrofolate. 775 
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Table 1. Dietary methyl donors: sources, forms and functions 776 
 Source Food Forms Functions 
Methionine 
(g/100 g) 
Brazil nut 1.12 Chicken 0.79 
Beef and pork 0.77  
Cheese 0.52 
Eggs 0.40 
L- Methionine 
Central molecule in one-carbon metabolism 
Precursor to  S-adenosylmethionine  
Influences maximal lifespan in mammals 
Normal growth and development 
Folate 
(Vitamin B-9) 
(μg/100 g) 
Spinach 199 
Beans 149 
Broccoli 108 
Avocado 89 
Beets 80 
Eggs 51 
Folic acid 
Tetrahydrofolic acid, 
Methyltetrahydrofolate 
Methenyltetrahydrofolate Folinic 
acid  
 
Formation of  S-adenosylmethionine 
May lower homocysteine levels 
 
Vitamin B-12 
(μg/100 g)  
Fish 6.22 
Beef 1.68 
Eggs 0.89 
Yogurt 0.52 
Poultry 0.36 
Methyl cobalamin 
5-deoxyadenosylcobalamin  
Formation of  S-adenosylmethionine   
Red blood cell formation, neurological function 
and DNA synthesis 
 
Choline 
(mg/100 g) 
Egg yolk 689 
Liver 330  
Wheat germ 180 
Soybeans 120  
Meat 100  
Salmon 79  
Phosphatidylcholine, Lecithin  
Choline bitartrate 
Choline choride  
Phosphatidylcholine syntheses (vital 
phospholipid for cell membranes) 
Precursor for the neurotransmitter acetylcholine 
(central role in brain development) 
Oxidized, in the liver and kidney, or 
metabolized by gut bacteria to betaine (indirect 
methyl group donor for one-carbon 
metabolism) 
 
Betaine 
(mg/100 g)  
Quinoa 630 
Wheat germ 410 
Bran 320 
Spaghetti 140 
Beets 130 
Spinach 120 
Seafood 23 
Betaine HCl Essential for one-carbon metabolism 
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